BIOLASE Balance Sheet Health
Financial Health criteria checks 2/6
BIOLASE has a total shareholder equity of $269.0K and total debt of $14.0M, which brings its debt-to-equity ratio to 5207.1%. Its total assets and total liabilities are $34.4M and $34.1M respectively.
Key information
5,207.1%
Debt to equity ratio
US$14.01m
Debt
Interest coverage ratio | n/a |
Cash | US$6.39m |
Equity | US$269.00k |
Total liabilities | US$34.08m |
Total assets | US$34.35m |
Recent financial health updates
Recent updates
Biolase partners with dental speciality programs across U.S.
Aug 31BIOLASE: Ongoing Operating Losses, Capital Raises To Sustain Liquidity
Jul 21BIOLASE amends senior secured term loan with SWK Funding
Jul 01BIOLASE: Bad News Across The Board - Sell
Mar 21Is BIOLASE (NASDAQ:BIOL) Weighed On By Its Debt Load?
Feb 24BIOLASE - Speculative Buy After Strong Preliminary Q4 Results
Jan 11BIOLASE - Good News Across The Board But Still Only Suited For The Most Speculative Investors
Nov 24Is BIOLASE (NASDAQ:BIOL) Using Debt Sensibly?
Jul 14Biolase shares jump 11% after regaining Nasdaq compliance
Feb 04Biolase: Business Recovery On The Way But Warrant Overhang Should Keep Investors Sidelined
Feb 01Financial Position Analysis
Short Term Liabilities: BIOL's short term assets ($25.0M) exceed its short term liabilities ($21.4M).
Long Term Liabilities: BIOL's short term assets ($25.0M) exceed its long term liabilities ($12.7M).
Debt to Equity History and Analysis
Debt Level: BIOL's net debt to equity ratio (2830.5%) is considered high.
Reducing Debt: BIOL's debt to equity ratio has increased from 156.4% to 5207.1% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: BIOL has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: BIOL has less than a year of cash runway if free cash flow continues to reduce at historical rates of 8.6% each year